A reply

Harper, N.J.N.

doi:10.1111/j.1365-2044.2009.06177_2.x

Cited by 6 publications

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Harper emphasised in his commentary [21] that rocuronium must be separated from IgE‐binding sites and eliminated rapidly so that its plasma concentration will quickly fall, preventing further interaction with IgE receptors via encapsulation. Leysen and colleagues, sharing the same concerns, designed an in vitro study [22] that showed that rocuronium encapsulated in sugammadex is unable to activate basophils.…”

Section: Discussionmentioning

confidence: 99%

Effects of sugammadex and rocuronium mast cell number and degranulation in rat liver

Tomak

Yılmaz²,

Bostan

et al. 2012

Anaesthesia

View full text Add to dashboard Cite

SummaryWe investigated the effect of rocuronium-and sugammadex-induced mast cell increase and degranulation in rat portal triads. Forty-two rats, in six groups, received either rocuronium 1 mg.kg ; rocuronium 1 mg.kg )1 and 5 min later, sugammadex 15 mg.kg; rocuronium 1 mg.kg )1 and 5 min later, sugammadex 100 mg.kg; or isotonic saline. Total mast cell numbers were significantly higher with rocuronium only, than in all other groups (p < 0.003), although in all active groups, the number was greater than the control. Total mast cell number was significantly higher with rocuronium and low-dose sugammadex compared with low-dose sugammadex only. The number of tryptase-positive mast cells with rocuronium only was significantly higher than in all other groups (p < 0.003). Tryptase-positive mast cell numbers in both groups receiving both rocuronium and sugammadex were significantly higher compared with both groups receiving sugammadex only. Rocuronium increased mast cell numbers, and degranulation was mitigated by sugammadex. These results suggest that sugammadex may be beneficial in treatment of rocuronium-induced anaphylaxis.

show abstract

Section: Discussionmentioning

confidence: 99%